Urgent Recall of Flebogamma 5% DIF Medication in Israel Due to Adverse Reactions
Translated & summarized from Ice by baba
Israel's Ministry of Health and distributor Medici Medical have initiated an urgent recall of a specific batch of Flebogamma 5% DIF medication due to a higher-than-usual number of hypersensitivity reactions. Other batches of the intravenous immunoglobulin treatment are safe for use. The recall affects pharmacies and clinics, with instructions for returning the affected batch for a refund. The drug is used to treat immunodeficiency and autoimmune diseases.
The story in 5 lines · by baba
- A specific batch of Flebogamma 5% DIF medication is being recalled in Israel.
- The recall is due to an unusual frequency of hypersensitivity reactions reported by patients.
- The Israeli Ministry of Health and distributor Medici Medical announced the recall.
- Other batches of the drug are safe and can continue to be used.
- Pharmacies and clinics must stop dispensing the affected batch and return it for a refund.
The Israeli Ministry of Health and Medici Medical, the distributor of Flebogamma 5% DIF, announced an urgent recall of a specific batch of the intravenous immunoglobulin treatment. The decision stems from an unusual frequency of hypersensitivity reactions reported by patients who received medication from this particular batch. While other batches of the drug remain safe for use, the precautionary recall was initiated due to the availability of alternative treatments. The recall is classified as a Level II recall, affecting pharmacies, hospital clinics, and commercial establishments. Those in possession of the affected batch are instructed to immediately cease dispensing it, move the items to a designated quarantine area, and return them to the "Susana" trading company for a refund. Flebogamma 5% DIF, manufactured by GRIFOLS, contains human antibodies and is used for replacement therapy in patients with primary or secondary immunodeficiency. It also helps regulate the immune system in various autoimmune and inflammatory conditions, such as ITP, Guillain-Barré syndrome, and Kawasaki disease.
